AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
CVRx Inc (NASDAQ:CVRX)
6.7 USD
+0.240 3.715%Sponsored Reports
Loading...
| Previous Close (in USD) | 6.46 |
|---|---|
| Change | +0.240 3.715% |
| 52 W H/L (in USD) | 33.135/7.020 |
| EBITDA (in USD) | -52.649M |
| PE Ratio | -- |
| Volume | 99269 |
| Diluted Eps TTM | -2.48 |
| Total Assets (in USD) | 115.229M |
|---|---|
| Total Liabilities (in USD) | 39.282M |
| Revenue TTM (in USD) | 42.086M |
| Cash (in USD) | 90.569M |
| Market Cap (in USD) | 160.887 M |
| Revenue Per Share TTM | 2.015 |
| Gross Profit TTM (in USD) | 17.47M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
CVRx Inc
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Employees: 200
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Nadim Yared | CEO, Pres & Director | 1968 |
| 2. | Mr. Jared Oasheim | Chief Financial Officer | 1983 |
| 3. | Mr. Paul Verrastro | Chief Marketing & Strategy Officer | 1963 |
| 4. | Mr. Paul Pignato | VP of Operations | NA |
| 5. | Mr. Craig Palmer | Sr. VP of US Sales | 1977 |
| 6. | Mr. Kevin Hykes | President, CEO & Director | 1966 |
| 7. | Mr. Jared Oasheim | Chief Financial Officer | 1984 |
| 8. | Mr. Paul Pignato | Vice President of Operations | NA |
| 9. | Ms. Jonelle R. Burnham | Vice President & General Counsel | 1971 |
| 10. | Mr. Craig Palmer | Senior Vice President of US Sales | 1977 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
-0.365 0.273% | 134.79 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+0.280 0.073% | 385.42 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
+0.063 0.072% | 87.29 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
-1.710 1.663% | 103.1 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -41.319M | -42.987M | -14.024M | -14.56M |
| Minority Interest | - | - | - | - |
| Net Income | -41.428M | -43.078M | -14.109M | -14.633M |
| Selling General Administrative | 50.045M | 27.863M | 9.717M | 6.106M |
| Gross Profit | 17.47M | 9.396M | 4.613M | 4.574M |
| Reconciled Depreciation | 0.412M | 0.168M | 0.075M | 0.056M |
| Ebit | -42.527M | -25.968M | -11.514M | -10.194M |
| Ebitda | -41.154M | -40.768M | -11.479M | -12.784M |
| Depreciation And Amortization | 1.373M | -14.8M | 0.035M | -2.59M |
| Operating Income | -42.527M | -25.968M | -11.514M | -10.194M |
| Other Operating Expenses | 64.996M | 39.004M | 17.567M | 16.451M |
| Interest Expense | 0.165M | 2.219M | 2.47M | 1.72M |
| Tax Provision | 0.109M | 0.091M | 0.085M | 0.073M |
| Interest Income | - | - | - | - |
| Net Interest Income | -0.165M | -2.219M | -2.47M | -1.72M |
| Income Tax Expense | 0.109M | 0.091M | 0.085M | 0.073M |
| Total Revenue | 22.469M | 13.036M | 6.053M | 6.257M |
| Total Operating Expenses | 59.997M | 35.364M | 16.127M | 14.768M |
| Cost Of Revenue | 4.999M | 3.64M | 1.44M | 1.683M |
| Total Other Income Expense Net | 1.208M | -17.019M | -2.51M | -4.366M |
| Net Income From Continuing Ops | -41.428M | -43.078M | -14.109M | -14.633M |
| Net Income Applicable To Common Shares | -41.428M | -43.078M | -14.326M | -14.646M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 115.229M | 124.937M | 152.548M | 64.777M | 29.107M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.987M | 4.223M | 2.585M | 0.605M | 0.375M |
| Total Liab | 39.282M | 15.757M | 6.589M | 358.015M | 308.15M |
| Total Stockholder Equity | 75.947M | 109.18M | 145.959M | -293.238M | -279.043M |
| Other Current Liab | 5.98M | 6.147M | 5.398M | 7.494M | 8.177M |
| Common Stock | 0.209M | 0.207M | 0.204M | 0.004M | 0.005M |
| Capital Stock | 0.209M | 0.207M | 0.204M | 0.004M | 0.005M |
| Retained Earnings | -477.381M | -436.182M | -394.754M | -351.676M | -337.567M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.027M | 0.026M | 0.026M | 0.026M |
| Cash | 90.569M | 106.194M | 142.072M | 59.112M | 25.741M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.864M | 8.088M | 5.908M | 7.977M | 8.614M |
| Current Deferred Revenue | -0.231M | - | - | - | - |
| Net Debt | -59.956M | -99.108M | -142.072M | -39.834M | -6.749M |
| Short Term Debt | 0.231M | 0.222M | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 30.613M | 7.086M | - | 19.278M | 18.992M |
| Other Stockholder Equity | 553.326M | 545.362M | 388.159M | 58.624M | 58.708M |
| Property Plant Equipment | - | 1.698M | 1.425M | 0.41M | 0.174M |
| Total Current Assets | 112.09M | 122.878M | 151.097M | 64.341M | 28.907M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 7.551M | 5.504M | 2.56M | 1.281M | 0.719M |
| Long Term Debt | 29.222M | 6.747M | - | 19.278M | 18.992M |
| Inventory | 10.983M | 6.957M | 3.88M | 3.343M | 2.072M |
| Accounts Payable | 1.884M | 1.719M | 0.51M | 0.483M | 0.437M |
| Accumulated Other Comprehensive Income | -0.207M | -0.207M | -0.198M | -0.19M | -0.189M |
| Non Currrent Assets Other | 0.027M | 0.027M | 0.026M | 0.026M | 0.026M |
| Non Current Assets Total | 3.139M | 2.059M | 1.451M | 0.436M | 0.2M |
| Capital Lease Obligations | 1.391M | 0.117M | - | - | - |
| Long Term Debt Total | - | 6.747M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -0.685M | -1.183M | -0.311M | -0.106M |
| Total Cashflows From Investing Activities | -0.685M | -1.183M | -0.311M | -0.106M |
| Total Cash From Financing Activities | 7.493M | 111.883M | 49.783M | 29.549M |
| Net Income | -41.428M | -43.078M | -14.109M | -14.633M |
| Change In Cash | -35.878M | 82.96M | 33.371M | 16.653M |
| Begin Period Cash Flow | 142.072M | 59.112M | 25.741M | 9.088M |
| End Period Cash Flow | 106.194M | 142.072M | 59.112M | 25.741M |
| Total Cash From Operating Activities | -42.677M | -27.732M | -16.096M | -12.785M |
| Depreciation | 0.412M | 0.168M | 0.075M | 0.056M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | -3.077M | -0.537M | -1.271M | -0.216M |
| Sale Purchase Of Stock | 0.771M | -0.001M | - | - |
| Other Cashflows From Financing Activities | 7.309M | 0.023M | -0.311M | 44.21M |
| Capital Expenditures | 0.685M | 1.183M | 0.311M | 0.106M |
| Change In Working Capital | -5.573M | -1.582M | -2.851M | -1.335M |
| Other Non Cash Items | 0.025M | 0.229M | 0.286M | 0.195M |
| Free Cash Flow | -43.362M | -28.915M | -16.407M | -12.891M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 351348 |
| 2. | iShares Russell 2000 ETF | 1 year ago | 255238 |
| 3. | Emerald Growth A | 1 year ago | 202841 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 165802 |
| 5. | Principal SmallCap Growth I Instl | 1 year ago | 136027 |
| 6. | Lord Abbett Micro Cap Growth I | 1 year ago | 134465 |
| 7. | Fidelity Small Cap Index | 1 year ago | 115183 |
| 8. | Royce Smaller-Companies Growth Svc | 1 year ago | 114000 |
| 9. | Mairs & Power Small Cap | 1 year ago | 98605 |
| 10. | Mairs & Power Small Cap Composite | 1 year ago | 98605 |
| 11. | iShares Russell 2000 Growth ETF | 1 year ago | 81798 |
| 12. | Silvercrest U.S. Small Cap Growth | 1 year ago | 79404 |
| 13. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 70000 |
| 14. | Empower Small Cap Growth/Emerald SP | 1 year ago | 67947 |
| 15. | Fidelity Extended Market Index | 1 year ago | 66276 |
| 16. | 1290 VT Micro Cap K | 1 year ago | 59163 |
| 17. | AST Small-Cap Growth | 1 year ago | 47470 |
| 18. | Vanguard Russell 2000 ETF | 1 year ago | 41689 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 41000 |
| 20. | SEI Tax-Managed Small/Mid Cap F (SIMT) | 1 year ago | 33796 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Johnson & Johnson | 1 year ago | 3495575 |
| 2. | NEA Management Company, LLC | 1 year ago | 2370542 |
| 3. | BlackRock Inc | 1 year ago | 803434 |
| 4. | Lord, Abbett & Co LLC | 1 year ago | 774670 |
| 5. | Vanguard Group Inc | 1 year ago | 594312 |
| 6. | Emerald Advisers, LLC | 1 year ago | 487519 |
| 7. | Balyasny Asset Management LLC | 1 year ago | 407008 |
| 8. | Emerald Mutual Fund Advisers Trust | 1 year ago | 385034 |
| 9. | Archon Capital Management LLC | 1 year ago | 285517 |
| 10. | Geode Capital Management, LLC | 1 year ago | 249543 |
| 11. | Parkman Healthcare Partners LLC | 1 year ago | 240000 |
| 12. | State Street Corporation | 1 year ago | 202257 |
| 13. | Silvercrest Asset Management Group LLC | 1 year ago | 148770 |
| 14. | EAM Investors, LLC | 1 year ago | 140768 |
| 15. | Amvescap Plc. | 1 year ago | 137389 |
| 16. | Royce & Associates, LP | 1 year ago | 114000 |
| 17. | Morgan Stanley - Brokerage Accounts | 1 year ago | 109640 |
| 18. | Mairs & Power Inc | 1 year ago | 99903 |
| 19. | Northern Trust Corp | 1 year ago | 95197 |
| 20. | Renaissance Technologies Corp | 1 year ago | 55900 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...